ASND
Ascendis Pharma A/S
Stock
$227.87+0.56 (+0.25%)Close Oct 2, 2026
Cash flow statement
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | €54M | −€306M | −€467M | −€496M | −€418M | −€272M | −€176M | −€139M | −€95M | −€60M | −€43M |
| Capital expenditures | — | — | €2.4M | €14M | €24M | €20M | €5.2M | €2.6M | €941K | €672K | €1.0M |
| Free cash flow | — | — | −€470M | −€510M | −€441M | −€291M | −€181M | −€141M | −€96M | −€61M | −€45M |
| Stock-based compensation | €116M | €96M | €67M | €64M | €67M | €53M | €37M | €20M | €9.7M | €7.3M | €1.7M |
| Buybacks | €17M | €0 | €0 | €105M | €22M | — | — | — | — | — | — |
| Free cash flow margin | — | — | −176.1% | −997.0% | −5,674.4% | −4,191.1% | −1,354.0% | −1,336.8% | −6,277.1% | −1,321.1% | −548.2% |